A phase I clinical and pharmacokinetic study of capecitabine (Xeloda ) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours by Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R

Get full text

High prognostic significance of residual disease after neoadjuvant chemotherapy : a retrospective study in 710 patients with operable breast cancer by AMAT, Sophie, ABRIAL, Catherine, CURE, Hervé, CHOLLET, Philippe, PENAULT-LLORCA, Frédérique, DELVA, Rémi, BOUGNOUX, Philippe, LEDUC, Bernard, MOURET-REYNIER, Marie-Ange, MERY-MIGNARD, Dominique, BLEUSE, Jean-Pierre, DAUPLAT, Jacques

Get full text

A Phase II study of irinotecan in patients with advanced renal cell carcinoma by Fizazi, Karim, Rolland, Frédéric, Chevreau, Christine, Droz, Jean‐Pierre, Mery‐Mignard, Dominique, Culine, Stéphane, Escudier, Bernard

Get full text

Risk announcement in paediatric cancerology: strengthen the therapeutic alliance by Doz, F, Davous, D, Seigneur, E, Heard, M

Get full text

P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC by Diéras, V, Bonnefoi, H, Alba, E, Awada, A, Coudert, B, Pivot, X, Gligorov, J, Jäger, A, Gianni, L, Lindeman, G, Pham, N, Su, Y, Gao, G, Mery-Mignard, D, Paridaens, R, Verweij, J

Get full text

Relationship between high dose irinotecan (260mg/m2) and response rate, without increased toxicities in metastatic colorectal cancer (MCRC) combination with bi-weekly 5FU/FA in a p... by Ducreux, M., Raoul, J., Merrouche, Y., Marti, P., Risse, M., Mery-mignard, D., Ferment, O., Boige, V.

Get full text